Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair.
Various mechanisms have been implicated in nitrogen mustard drug resistance. The role of these mechanisms in the development of chlorambucil drug resistance in chronic lymphocytic leukemia (CLL) is discussed. We review these mechanisms with emphasis on the emerging role of DNA repair, and specifically, recombinational repair. Inhibition of these repair processes may lead to new therapies, not only in CLL, but in other malignancies as well.
Panasci
L
L
Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada. L.Panasci@hotmail.com
Paiement
J P
JP
Christodoulopoulos
G
G
Belenkov
A
A
Malapetsa
A
A
Aloyz
R
R
D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D017209:Apoptosis; D001692:Biological Transport; D002699:Chlorambucil / Q000494:pharmacology*; D003432:Cross-Linking Reagents / Q000494:pharmacology; D004260:DNA Repair; D019008:Drug Resistance, Neoplasm; D016158:Genes, p53 / Q000235:genetics; D005978:Glutathione / Q000235:genetics; D005982:Glutathione Transferase / Q000235:genetics; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000378:metabolism*; D008466:Mechlorethamine / Q000494:pharmacology*; D008957:Models, Genetic; D009154:Mutation; D011995:Recombination, Genetic
D018906:Antineoplastic Agents, Alkylating; D003432:Cross-Linking Reagents; D002699:Chlorambucil; D008466:Mechlorethamine; D005982:Glutathione Transferase; D005978:Glutathione